Professional Documents
Culture Documents
Ovarian Reserve in Young Juvenile Idiopathic Arthritis Patients 2018
Ovarian Reserve in Young Juvenile Idiopathic Arthritis Patients 2018
To cite this article: Gabriela R.V. Ferreira, Renato B. Tomioka, Nadia E. Aikawa, Elaine P. Leon,
Gustavo A.R. Maciel, Paulo C. Serafini, Edmund C. Baracat, Claudia Goldenstein-Schainberg,
Rosa M.R. Pereira, Eloisa Bonfá & Clovis A. Silva (2018): Ovarian Reserve in Young Juvenile
Idiopathic Arthritis Patients, Modern Rheumatology, DOI: 10.1080/14397595.2018.1465646
a b,c a,b b
Gabriela R.V. Ferreira, Renato B. Tomioka, Nadia E. Aikawa, Elaine P. Leon, Gustavo A.R.
c c c b
Maciel, Paulo C. Serafini, Edmund C. Baracat, Claudia Goldenstein-Schainberg, Rosa M.R.
b b a,b
Pereira, Eloisa Bonfá, Clovis A. Silva
t
ip
a
Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina da
cr
b
Division of Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina da
Av. Dr. Eneas Carvalho Aguiar, 647 - Cerqueira César, São Paulo – SP, Brazil, 05403-000
Objectives: Juvenile idiopathic arthritis (JIA) occurs during reproductive age, however, there are not
Methods: Twenty-eight post-pubertal JIA patients and age-matched 28 healthy controls were studied.
Complete ovarian function was assessed during the early follicular phase of the menstrual cycle
including anti-Müllerian hormone (AMH), estradiol, luteinizing hormone (LH), follicle stimulating
hormone (FSH) and antral follicle count (AFC) by ovarian ultrasound, and anti-corpus lutheum
antibodies (anti-CoL). Demographic data, menstrual abnormalities, disease parameters and treatment
t
Results: The mean current age (22.6±6.59 vs. 22.5±6.59 years, p=0.952) was similar in JIA patients
ip
and healthy controls with a higher median menarche age [13(8-16) vs. 12(8-14) years, p=0.029]. A
cr
lower median AMH levels [2.65(0.47-9.08) vs. 4.83(0.74-17.24)ng/mL,p=0.029] with a higher LH
[8.44±4.14 vs. 6.03±2.80IU/L, p=0.014] and estradiol levels [52.3(25.8-227.4) vs. 38.9(26.2-133.6)
us
pg/mL, p=0.008] were observed in JIA compared to control group. Anti-CoL and AFC were similar in
both groups (p>0.05). Further analysis of JIA patients revealed that current age, disease duration,
an
number of active/limited joints, ESR, CRP, patient/physician VAS, JADAS 71, DAS 28, CHAQ, HAQ,
M
patient/parents PedsQL, PF-SF 36, cumulative glucocorticoid and cumulative methotrexate doses
were not correlated with AMH, FSH, estradiol levels or AFC (p>0.05).
ed
Conclusions: The present study was the first to suggest diminished ovarian reserve, not associated
to hypothalamic pituitary gonadal axis, in JIA patients during reproductive age. The impact of this
pt
Keywords: Juvenile idiopathic arthritis; ovarian reserve; anti-Müllerian hormone; fertility, anti-corpus
lutheum antibodies.
Ac
Introduction
by chronic arthritis of unknown etiology with onset before age of 16 years [1-3]. This chronic
inflammatory disease occurs mainly in females during the reproductive age, and ovarian reserve and
Evaluation of complete female gonadal function in juvenile rheumatic diseases including new
ovarian reserve markers such as anti-Müllerian hormone (AMH) levels and ovarian ultrasound [4-7],
and anti-corpus lutheum antibodies (anti-CoL) [7,8] was limited to childhood-onset systemic lupus
t
Thus, the objective of the present study was to assess ovarian reserve and anti-Col in JIA
ip
patients compared to healthy controls. The possible association between ovarian parameters and
cr
demographic data, gynecological history, clinical and laboratorial parameters of disease activity,
Methods
us
an
A cross-section study was conducted from September 2014 to June 2016 and all 110 female
M
JIA patients, aged between 15 to 40 years, were invited. JIA patients fulfilled the International League
of Associations for Rheumatology (ILAR) classification criteria [11] and were followed at the Pediatric
ed
The exclusion criteria were: contraindication or refusal to stop hormonal contraceptives for at
pt
least 6 months or until return of menstruation for 3 consecutive months or refusal to participate in this
study (n=64), amenorrhea (n=3), thyroid diseases (n=6), current gestation or lactation (n=3),
ce
polycystic ovarian syndrome (n=2), presence of another systemic autoimmune disease (n=2), obesity
in virgin patients, due to the difficulty performing the abdominal ultrasonography (n=1) and
Ac
hypothalamic pituitary gonadal axis dysfunction (n=1). None of them had history of gynecological
surgery, pelvic irradiation due to neoplasia, use of gonadotrophin releasing hormone analogs, end-
stage renal disease or premature ovarian insufficiency [sustained amenorrhea before the age of 40
years, increased follicle-stimulating hormone (FSH) and decreased estrogen levels] [7]. Thus, after
the exclusion of 82 patients, 28 post-pubertal JIA patients were studied. The healthy age-matched
control group included 28 post-pubertal females adolescents or young adults, between 15 and 40
years of age, selected consecutively using the same exclusion criteria. The Local Ethics Committee
of our tertiary service approved the study and an informed consent was obtained from all participants
Demographic data: The demographic data included: current age, ethnicity, socio economic class
[12], disease duration and body mass index (BMI). BMI was defined as weight in kilograms divided by
2
the square of height (m ).
Gynecological evaluation: Age at JIA menarche and controls were registered based on recollection.
t
Menstrual flow duration and cycle length were evaluated prospectively for at least 3 consecutive
ip
months. Normal cycle was defined as flow duration varying from 3 to 7 days and length from 25 to 35
cr
days [13-14]. Menstrual disturbances were based on alterations in one or more of these parameters
during evaluation. The mean cycle length and flow duration were also calculated. Amenorrhea was
us
defined as the absence of menstrual periods for three consecutive cycles or a time period of more
than six months in a woman who was previously menstruating [13-14]. The presence of
an
dysmenorrhea, menorrhagia, premenstrual syndrome, presence of cervical mucus and mid-menstrual
M
Ovarian reserve parameters: Complete ovarian function and other hormone profiles were assessed
in the first five days of menstrual cycle. The hormones were collected in fast morning, between 8 to 9
pt
AM. These hormones were evaluated blinded to the other parameters of ovarian function. Follicle-
stimulating hormone (FSH), luteinizing hormone (LH), estradiol, morning total testosterone,
ce
(Roche Diagnostics, Cobas 6000 analyzer series, Mannheim, Germany). Intra and inter-assay
Ac
coefficients of variation were recommended by the manufacturer and limited to 2.2-5.1% and 1.9-
8.4%, respectively. AMH was measured by chemiluminescence assay (AMH, Beckman Coulter,
UniCel Dxi 800, Brea, CA) and intra and inter-assay coefficients of variation were limited to 9 and
7.8%, respectively.
Transvaginal ultrasound exams were performed by the same person (RBT), with a 4-10 MHz
endovaginal or a 2-8 MHz abdominal probe (Voluson S6, GE Healthcare Ultrasound). Antral follicle
count (AFC) and measurement of the ovarian volumes were performed through transvaginal
ultrasound (in sexually active patients and healthy controls) or abdominal (in virgin patients and
healthy controls) in the Discipline of Gynecology at the same university hospital. The AFC number was
counted during the early follicular phase, taking into account the number of follicles between 2 and 10
mm [15]. Ovaries were measured in 3 perpendicular planes and the ovarian volumes were calculated
using the ellipsoid formula (volume = D1 x D2 x D3 x 0.523), where D1, D2 and D3 are the maximum
Diminished ovarian reserve (DOR) was characterized by AMH levels < 1.0 ng/mL or AFC < 7
[17].
t
ip
Detection of anti-corpus luteum antibody: Serum reactivity to the 67 kDa protein from corpus
cr
luteum was assessed by immunoblotting in duplicated samples from JIA patients and controls, as
previously described [18]. Crude tissue and cell extracts, obtained from bovine corpus luteum (100
us
µg/well), were submitted to polyacrylamide gel electrophoresis under denaturating and reducing
milk in PBS) and immunoprobed by incubation with diluted serum samples 1/10. Reactivity was
tagged with anti-human IgG alkaline phosphatase conjugate and visualized using appropriate
ed
chromogenic substrates.
pt
Clinical assessment of JIA patients included: number of active and limited joints, patient and
ce
physician global assessment of arthritis activity measured in a 10cm horizontal visual analogy scale
(VAS). Disease activity was evaluated by the Juvenile Arthritis Disease Activity Score (JADAS71)
Ac
(range: 0-101 points) for patients up to 18 years [19] and by the Disease Activity Score 28-Joint
Counts (DAS28) for patients over 18 years [20]. Validated Brazilian version of Childhood Health
Assessment Questionnaire (CHAQ) [21] was used for patients younger than 18 years of age and
Health Assessment Questionnaire (HAQ) for patients older than 18 years [22]. Health-related quality
of life was evaluated with Brazilian version of the Pediatric Quality of Life Inventory (PedsQL) for
patients up to 18 years [23] and short-form 36-item questionnaire (SF-36) for patients older than 18
years [24].
cyclophosphamide and biological agents (etanercept, adalimumab, abatacept and tocilizumab) were
systematically assessed.
Statistical analysis: The results for the continuous variables were presented by median (minimum
and maximum value) or mean standard deviation (SD), and for categorical variables presented as
t
frequency (percentage). The scores that had normal and abnormal distributions were compared by
ip
Student's t-test and Mann-Whitney test, respectively. The differences of categorical variables were
cr
calculated by Fisher's exact test or Pearson chi-square test, as appropriated. Pearson or Spearman
rank correlation coefficients were used for correlations between ovarian reserve parameters and
us
demographic, disease and treatment variables. The adopted significance level in all analyses was set
an
at 5%.
M
Results
According to disease subtype, oligoarticular onset JIA was observed in 3/28 (11%) patients,
ed
polyarticular onset in 19/28 (68%), systemic onset in 5/28 (18%) and enthesitis-related arthritis in 1/28
(3%). DOR was similar in JIA patients and controls (11% vs. 11%, p=1.000).
pt
Table 1 shows demographic data and gynecological evaluation of JIA patients and healthy
controls. The mean current age (22.6 ± 6.59 vs. 22.5 ± 6.59 years, p=0.952) was similar in JIA
ce
patients and healthy controls with a higher median menarche age [13 (8-16) vs. 12 (8-14) years,
p=0.029]. No differences were observed of menstrual cycles parameters in both groups (p>0.05, Table
Ac
1)
Table 2 illustrates hormone profile and other ovarian parameters and anti-CoL in JIA patients
and healthy controls. A lower median of AMH levels was observed in JIA patients compared to
controls [2.65 (0.47-9.08) vs. 4.83 (0.74-17.24) ng/mL, p=0.029]. A higher LH (8.44 ± 4.14 vs. 6.03 ±
2.80IU/L, p=0.014) and estradiol levels [52.3 (25.8-227.4) vs. 38.9 (26.2-133.6) pg/mL, p=0.008] were
observed in JIA versus controls. Anti-CoL (3% vs. 3%, p=1.0) and AFC [16.5 (6-57) vs. 20 (2-37),
Regarding Pearson or Spearman’s rank correlations for JIA patients, current age, disease
duration, number of active/limited joints, ESR, CRP, patient/physician VAS, JADAS 71, DAS 28,
CHAQ, HAQ, patient/parents PedsQL, PF-SF 36, cumulative glucocorticoid and cumulative
methotrexate doses were not correlated with AMH, FSH, estradiol levels or AFC (p>0.05).
No differences were observed between JIA patients that received cumulative dose of
methotrexate 5 g (n=14) compared to those that received cumulative dose of methotrexate < 5 g
(n=12) in respect to ovarian parameters: FSH (6.89 1.21 vs. 7.20 2.30 IU/L, p=0.674), LH [6.9 (2.4-
t
13.2) vs. 8.3 (4.1-23.2) IU/L, p=0.777], estradiol [54 (35.5-160.2) vs. 52.5 (25.8-227.4) pg/mL,
ip
p=0.857], AMH [2.24 (0.47-8.85) vs. 3.01 (1.03-9.08) ng/mL, p=0.554], right ovarian volume (4.39
cr
1.66 vs. 6.17 2.88 cm , p=0.071), left ovarian volume [5.8 (2.2-27.1) vs. 5.4 (2.7-8) cm , p=0.662]
3 3
us
and AFC [13.5 (8-40) vs. 17.5 (6-57), p=0.247]
No differences were evidenced between JIA patients that received biological agents (n=17)
an
compared to those that did not receive these medications (n=11) regarding to all evaluated ovarian
parameters: FSH (6.91 1.89 vs. 7.04 1.78 IU/L, p=0.860), LH [7.8 (4.2-23-2) vs.7.9 (2.4-16) IU/L,
M
p=0.778] estradiol [47.4 (25.8-227.4) vs. 57.1 (32.7-160.2) pg/mL, p=0.672], AMH levels [3.36 (0.64-
9.08) vs. 2.42 (0.47-6.47) ng/mL, p=0.323], right ovarian volume (5.47 2.31 vs. 5.07 2.72 cm ,
3
ed
3
p=0.677), left ovarian volume [6.3 (2.5-9.3) vs. 4.2 (2.2-27.1) cm , p=0.100] and AFC [16 (6-57) vs. 18
(8-34), p=0.906].
pt
No differences were evidenced between patients that JIA onset occurred before menarche
ce
(n=9) compared to those that menarche occurred after JIA onset (n=19) regarding the ovarian
parameters: FSH [6.2 (3.7-10.1) vs. 6.4 (4.7-12.2) IU/L, p=0.786), LH [6.5 (2.4-13.2) vs. 7.9 (4.2-23.2)
Ac
IU/L, p=0.460], estradiol [41.5 (25.8-227.4) vs. 53.5 (37.6-160.2) pg/mL, p=0.089], AMH levels [2.65
(0.64-6.47) vs. 3.36 (0.47-9.08) ng/mL, p=0.824], right ovarian volume [4.4 (3.2-8.6) vs. 5.6 (1.5-12.8)
3 3
cm , p=0.325), left ovarian volume [5.05 (2.2-27.1) vs. 5.6 (2.2-8.9) cm , p= 0.948] and AFC [14 (9-33)
The present study was the first to suggest diminished ovarian reserve, not associated to
The main strength of this study was a complete ovarian reserve evaluation in post-pubertal
JIA patients and age-matched healthy controls at early follicular phase of menstrual cycle that
provided a more accurate estimation of follicle population and oocyte quality [25-31]. In addition, the
standardization of blood collection was important, since FSH production has circadian variation [7]. We
excluded patients and healthy controls with amenorrhea, and therefore none of the subjects had
premature ovarian insufficiency. The rigorous selection criteria of our JIA patients and controls lower
t
than 40 years and without gynecologic diseases and hypothalamic-pituitary-ovary axis dysfunction
ip
were relevant since these abnormalities may influence ovarian reserve parameters [5-8,26-31].
cr
We also assessed hormone and anti-CoL profiles without the effect of any hormonal
contraceptives for at least three months to avoid possible bias, since AMH levels can be decreased in
us
women using these birth control methods [32]. However, a limitation was small sample size due to
defined herein as decreased AFC or decreased AMH levels [17]. The significant lower values of AMH
in JIA patients suggest a reduction of ovarian follicle population, despite comparable values of AFC. In
ed
fact, the latter has low sensitivity and high specificity [33].
Although basal serum FSH and estradiol are used as ovarian reserve markers, it has
pt
demonstrated to have low accuracy to DOR diagnosis, since the reliability of both hormones is limited
Premature ovarian failure was previously described from 3.5% to 7.5% of JIA, mainly reported
in older patients (mean age 35 years) [34] and under chlorambucil for amyloidosis [35]. None of our
Ac
JIA patients had this abnormality, because of their young age and also were never treated with this
DOR in pediatric and adult autoimmune rheumatic diseases may occur due to aging, disease
activity, autoimmunity, and the use of immunosuppressive agents [4-6,36-41]. The similar age
between post-pubertal JIA patients and controls exclude this confounding variable and support the
notion of precociously reduced ovarian reserve in JIA patients. Disease activity does not seem to
affect reproductive health in our female JIA, contrasting to Behçet disease in which disease flare was
the most important contributing factor for reduced ovarian reserve [27].
may impact developing follicles, sparing primordial follicles during early phase due to CD4+ T cells
activation, inducing progressive decrease of ovarian function in mice. In humans, there are several
reported target antigens involved in autoimmune oophoritis, such as zona pellucida/oocyte, granulosa
cells, theca cells, steroidogenic enzymes and corpus luteum (anti-Col) [7]. The presence of anti-Col
was rarely observed in our JIA patients, contrasting with a prevalence of 16-22% in adult and cSLE
populations [8,18].
t
Methotrexate seems to be not influence ovarian follicles population in JIA, contrasting with our
ip
previous study that demonstrated that a high cumulative methotrexate dose was a possible cause of
cr
ovarian dysfunction in adult c-SLE patients [8].
Biological agents do not seem to impair fertility in females [5,6], as also observed herein.
us
Regarding immunosuppressive agents, intravenous cyclophosphamide was not a contributing factor to
diminished ovarian reserve in JIA patients, distinct for reports in SLE [8,10] and JDM patients [9]. This
an
drug was used in solely in two patients with a total cumulative dose of less than 4 g and both had
M
Delayed menarche was observed in JIA patients as also observed in cSLE [10,35-37] and
ed
In conclusion, the present study suggests that JIA patients have diminished ovarian reserve.
pt
The impact of this abnormality in future fertility of these patients needs to be evaluated in prospective
studies.
ce
Funding: Supported by grants from Fundação de Amparo à Pesquisa do Estado de São Paulo
to CAS)), Federico Foundation (to RMRP, EB and CAS) and by Núcleo de Apoio à Pesquisa “Saúde
2. Pugliese C, van der Vinne RT, Campos LM, Guardieiro PR, Saviolli C, Bonfa E. Juvenile
idiopathic arthritis activity and function ability: deleterious effects in periodontal disease? Clin
Rheumatol. 2016;35:81-91.
3. Gualano B, Bonfa E, Pereira RM, Silva CA. Physical activity for paediatric rheumatic diseases:
4. Silva CA, Brunner HI. Gonadal functioning and preservation of reproductive fitness with juvenile
t
systemic lupus erythematosus. Lupus. 2007;16:593-9.
ip
5. Silva CA, Bonfa E, Østensen M. Maintenance of fertility in patients with rheumatic diseases
cr
needing antiinflammatory and immunosuppressive drugs. Arthritis Care Res (Hoboken).
2010;62:1682-90.
6.
us
Ostensen M, Brucato A, Carp H, Chambers C, Dolhain RJ, Doria A, et al. Pregnancy and
8. de Araujo DB, Yamakami LY, Aikawa NE, Bonfá E, Viana VS, Pasoto SG, et al. Ovarian reserve
ed
9. Aikawa NE, Sallum AM, Leal MM, Bonfá E, Pereira RM, Silva CA. Menstrual and hormonal
10. Aikawa NE, Sallum AM, Pereira RM, Suzuki L, Viana VS, Bonfa E, et al. Subclinical impairment
11. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International
1991;1-29.
13. Silva CA, Leal MM, Leone C, Simone VP, Takiuti AD, Saito MI et al (2002) Gonadal function in
adolescents and young women with juvenile systemic lupus erythematosus. Lupus.
2002;11:419-25.
14. Medeiros PB, Febronio MV, Bonfa E, Borba EF, Takiuti AD, Silva CA. Menstrual and hormonal
15. Hendriks DJ, Mol BW, Bancsi LF, Te Velde ER, Broekmans FJ. Antral follicle count in the
t
prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis
ip
and comparison with basal follicle-stimulating hormone level. Fertil Steril. 2005;83:291-301.
cr
16. Hendriks DJ, Kwee J, Mol BW, te Velde ER, Broekmans FJ. Ultrasonography as a tool for the
prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral
17.
follicle count. Fertil Steril. 2007;87:764-75.
18. Pasoto SG, Viana VS, Mendonca BB, Yoshinari NH, Bonfa E. Anti-corpus luteum antibody: a
ed
novel serological marker for ovarian dysfunction in systemic lupus erythematosus? J Rheumatol
1999;26:1087-93.
pt
composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658–
66.
Ac
20. van Riel PLCM. The development of the disease activity score (DAS) and the disease activity
21. Machado CS, Ruperto N, Silva CH, Ferriani VP, Roscoe I, Campos LM, et al. Paediatric
Rheumatology International Trials Organisation. The Brazilian version of the Childhood Health
Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp
Rheumatol. 2001;19:25–9.
22. Ferraz MB, Oliveira LM, Araujo PM, Atra E, Tugwell P. Crosscultural reliability of the physical
23. Klatchoian DA, Len CA, Terreri MT, Silva M, Itamoto C, Ciconelli RM, et al. Quality of life of
children and adolescents from São Paulo: reliability and validity of the Brazilian version of the
Pediatric Quality of Life Inventory version 4.0 Generic Core Scales. J Pediatr (Rio J).
2008;84:308-15.
24. Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR. Tradução para língua portuguesa
t
25. Yamakami LY, de Araujo DB, Silva CA, Baracat EC, de Carvalho JF. Severe hemorrhagic
ip
corpus luteum complicating anticoagulation in antiphospholipid syndrome. Lupus. 2011;20:523-
cr
6.
26. Mont'Alverne AR, Pereira RM, Yamakami LY, Viana VS, Baracat EC, Bonfá E, et al. Reduced
27.
us
ovarian reserve in patients with takayasu arteritis. J Rheumatol. 2014;41:2055-9.
Mont'Alverne AR, Yamakami LY, Gonçalves CR, Baracat EC, Bonfá E, Silva CA. Diminished
an
ovarian reserve in Behçet's disease patients. Clin Rheumatol. 2015;34:179-83.
M
28. Yamakami LY, Serafini PC, de Araujo DB, Bonfá E, Leon EP, Baracat EC, et al. Ovarian
29. Yamakami LY, Serafini PC, de Araujo DB, Bonfá E, Leon EP, Baracat EC, et al. Clark CA,
Laskin CA. Ovarian reserve in antiphospholipid syndrome: the jury is still out. Lupus 2015; 24:
pt
30. de Souza FH, Shinjo SK, Yamakami LY, Viana VS, Baracat EC, Bonfá E, et al. Reduction of
ce
ovarian reserve in adult patients with dermatomyositis. Clin Exp Rheumatol. 2015;33:44-9.
31. de Souza FH, da Silva CA, Yamakami LY, dos Santos Trindade Viana V, Bonfá E, Shinjo SK.
Ac
Reduced ovarian reserve in patients with adult polymyositis. Clin Rheumatol. 2015;34:1795-9.
32. Kristensen SL, Ramlau-Hansen CH, Andersen CY, Ernst E, Olsen SF, Bonde JP et al. The
association between circulating levels of antimüllerian hormone and follicle number, androgens,
33. Testing and interpreting measures of ovarian reserve: a committee opinion. Practice Committee
35. Packham JC, Hall MA. Premature ovarian failure in women with juvenile idiopathic arthritis (JIA).
36. Brouwer J, Laven JS, Hazes JM, Schipper I, Dolhain RJ. Levels of serum anti-
Müllerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis.
37. Henes M, Froeschlin J, Taran FA, Brucker S, Rall KK, Xenitidis T, et al. Ovarian reserve
t
of rheumatoid arthritis, Behçet's disease and spondyloarthritis on anti-Müllerian hormonelevels.
ip
Rheumatology (Oxford). 2015;54:1709-12.
cr
38. Karakus S, Sahin A, Durmaz Y, Aydin H, Yildiz C, Akkar O, et al. Evaluation of ovarian reserve
using anti-müllerian hormone and antral follicle count in Sjögren's syndrome: Preliminary study.
39.
J Obstet Gynaecol Res. 2017;43:303-7.
us
Silva CA, Leal MM, Leone C, Simone VP, Takiuti AD, Saito MI, et al. Gonadal function in
an
adolescents and young women with juvenile systemic lupus erythematosus. Lupus.
M
2002;11:419-25.
40. Febronio MV, Pereira RM, Bonfa E, Takiuti AD, Pereyra EA, Silva CA. Inflammatory
ed
41. Medeiros PB, Febrônio MV, Bonfá E, Borba EF, Takiuti AD, Silva CA. Menstrual and hormonal
t
0.162
ip
Presence of cervical mucus 19 (68) 17 (61) 0.585
Mid-menstrual cycle pain 11 (39) 11 (39) 1.000
Values expressed as n (%), median (range) or mean ± standard deviation.
cr
us
an
Table 2 - Hormone profile and other ovarian parameters and anti-corpus luteum antibody in
juvenile idiopathic arthritis (JIA) patients and healthy controls.
JIA Healthy controls
Variables p
M
(n=28) (n=28)
Hormone profiles and ovarian
parameters
FSH, IU/L 6.4 (3.7-12.2) 6.3 (2.6-12.7) 0.317
ed
3
Right ovarian volume, cm 4.9 (1.5-12.8) 6.1 (2-16.1) 0.099
3
Left ovarian volume, cm 5.1 (2.2-27.1) 5.6 (2.1-15.6) 0.966
AFC 16.5 (6-57) 20 (2-37) 0.222
Ac